
NASDAQHealthcareMedical - Specialties
最新数据
US$13.23
−US$0.19 · -1.42%
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
常规交易时段
US$13.23
−US$0.19 · -1.42%
盘中时间采用ET。市场数据可能有所延迟。
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
日内区间
当前US$13.23
52周区间
当前US$13.23
盘中时间采用ET。市场数据可能有所延迟。
QuidelOrtho Corporation specializes in the creation and production of diagnostic testing solutions, addressing a wide array of healthcare testing demands. The company operates through distinct business units. Its Labs division provides clinical chemistry and immunoassay instruments and tests designed to analyze bodily fluids and proteins, aiding in health assessment, patient management, and tracking disease progression. The Transfusion Medicine unit focuses on ensuring blood safety and compatibility by offering immunohematology and infectious disease screening tests for blood and plasma. For rapid results in various clinical environments, the Point-of-Care segment delivers quick diagnostic tests. Additionally, the Molecular Diagnostics arm develops advanced polymerase chain reaction thermocyclers, analyzers, and amplification systems. QuidelOrtho distributes its offerings both directly to end-users and through an extensive network of distributors. These products are utilized by professionals in settings such as medical offices, hospitals, clinical and reference laboratories, urgent care centers, universities, retail clinics, pharmacies, wellness screening centers, and blood/donor banks, as well as for individual, non-professional, and over-the-counter applications. Founded in 1979 and based in San Diego, California, the company maintains a global footprint, including operations across North America, Europe, the Middle East, Africa, and China.
日内区间
当前US$13.23
52周区间
当前US$13.23
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目(USD) | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 27.3亿 USD | 27.83亿 USD | 29.98亿 USD | 32.66亿 USD | 16.99亿 USD |
| 销货成本 | 14.56亿 USD | 14.96亿 USD | 15.01亿 USD | 13.3亿 USD | 4.2亿 USD |
| 毛利 | 12.74亿 USD | 12.87亿 USD | 14.97亿 USD | 19.36亿 USD | 12.78亿 USD |
| 研究与开发 | 1.86亿 USD | 2.19亿 USD | 2.47亿 USD | 1.88亿 USD | 9570万 USD |
| 销售、一般及管理费用 | 7.46亿 USD | 7.67亿 USD | 7.63亿 USD | 6.21亿 USD | 2.4亿 USD |
| 营业费用 | 21.93亿 USD | 32.47亿 USD | 13.58亿 USD | 10.93亿 USD | 3.72亿 USD |
| 利息收入 | — | — | 220万 USD | 130万 USD | 30万 USD |
| 利息支出 | 1.78亿 USD | 1.88亿 USD | 1.79亿 USD | 7450万 USD | 70万 USD |
| 折旧和摊销 | 4.42亿 USD | 4.53亿 USD | 4.57亿 USD | 2.84亿 USD | 5270万 USD |
| 营业利润 | −9.19亿 USD | −19.61亿 USD | 1.39亿 USD | 8.44亿 USD | 9.06亿 USD |
| 净利润 | −11.32亿 USD | −20.52亿 USD | −1010万 USD | 5.49亿 USD | 7.04亿 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化,并非 GoAI 建议。
平均目标
US$12.25
下跌空间 7.41%报告持有此股票敞口的交易所交易基金。
Avantis U.S. Small Cap Value ETFAVUV4657.52万0.15%308.51亿 USD0.25%US$120.21+0.48%
Vanguard Morningstar Total Stock Market ETFVTI3135.17万0.00%2.3万亿 USD0.03%US$381.39-0.14%
iShares Russell 2000 ETFIWM2443.26万0.03%787.4亿 USD0.19%US$278.15-0.28%
Vanguard Morningstar Small-Cap ETFVB2262.12万0.01%1853亿 USD0.03%US$288.67-0.28%
Vanguard Morningstar Small-Cap Value ETFVBR1437.84万0.02%682亿 USD0.05%US$234.99+0.24%
Vanguard Extended Market ETFVXF1146.61万0.01%954亿 USD0.05%US$233.82-0.50%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM846.03万0.05%158.4亿 USD0.03%US$53.535+0.16%
Vanguard Russell 2000 ETFVTWO571.53万0.03%180亿 USD0.06%US$112.36-0.27%
Avantis U.S. Small Cap Value ETFAVUV
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Morningstar Small-Cap ETFVB
Vanguard Morningstar Small-Cap Value ETFVBR
Vanguard Extended Market ETFVXF
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM
Vanguard Russell 2000 ETFVTWOAI 生成内容及延迟市场数据仅供信息与教育用途,不构成投资建议。